Literature DB >> 27761006

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

M O Holmström1,2, M D Hjortsø2, S M Ahmad2, Ö Met2,3, E Martinenaite2, C Riley1, P Straten2, I M Svane2,3, H C Hasselbalch1, M H Andersen2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27761006     DOI： 10.1038/leu.2016.290

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.

Authors:  Caroline H Riley; Marie K Brimnes; Morten Hansen; Morten Krogh Jensen; Hans C Hasselbalch; Lasse Kjaer; Per Thor Straten; Inge Marie Svane
Journal:  Eur J Haematol       Date:  2015-11-26       Impact factor: 2.997

2.  Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

Authors:  Zeyu Xiong; Yan Yan; Enli Liu; Richard T Silver; Srdan Verstovsek; Fan Yang; Hong Wang; Josef Prchal; Xiao-Feng Yang
Journal:  Clin Immunol       Date:  2006-11-17       Impact factor: 3.969

3.  High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.

Authors:  Ozcan Met; Eva Balslev; Henrik Flyger; Inge Marie Svane
Journal:  Breast Cancer Res Treat       Date:  2010-03-25       Impact factor: 4.872

Review 4.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

5.  JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Authors:  H Quentmeier; R A F MacLeod; M Zaborski; H G Drexler
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

7.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

8.  HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Authors:  Shamaila Munir; Gitte Holmen Andersen; Özcan Met; Marco Donia; Thomas Mørch Frøsig; Stine Kiaer Larsen; Tobias Wirenfeldt Klausen; Inge Marie Svane; Mads Hald Andersen
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

9.  Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.

Authors:  Abire Jedidi; Caroline Marty; Charleen Oligo; Laurence Jeanson-Leh; Jean-Antoine Ribeil; Nicole Casadevall; Anne Galy; William Vainchenker; Jean-Luc Villeval
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113

10.  Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis.

Authors:  Vibe Skov; Caroline Hasselbalch Riley; Mads Thomassen; Thomas Stauffer Larsen; Morten K Jensen; Ole Weis Bjerrum; Torben A Kruse; Hans Carl Hasselbalch
Journal:  Leuk Lymphoma       Date:  2013-05-15
View more
  30 in total

Review 1.  Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.

Authors:  Wingchi Leung; Helen E Heslop
Journal:  Cancer Immunol Res       Date:  2019-04       Impact factor: 11.151

Review 2.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 3.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

4.  Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Authors:  Fiorella Schischlik; Roland Jäger; Felix Rosebrock; Eva Hug; Michael Schuster; Raimund Holly; Elisabeth Fuchs; Jelena D Milosevic Feenstra; Edith Bogner; Bettina Gisslinger; Martin Schalling; Elisa Rumi; Daniela Pietra; Gottfried Fischer; Ingrid Faé; Loan Vulliard; Jörg Menche; Torsten Haferlach; Manja Meggendorfer; Anna Stengel; Christoph Bock; Mario Cazzola; Heinz Gisslinger; Robert Kralovics
Journal:  Blood       Date:  2019-05-07       Impact factor: 22.113

5.  The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-08-02       Impact factor: 8.110

6.  Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Authors:  Alessandro Prestipino; Alica J Emhardt; Konrad Aumann; David O'Sullivan; Sivahari P Gorantla; Sandra Duquesne; Wolfgang Melchinger; Lukas Braun; Slavica Vuckovic; Melanie Boerries; Hauke Busch; Sebastian Halbach; Sandra Pennisi; Teresa Poggio; Petya Apostolova; Pia Veratti; Michael Hettich; Gabriele Niedermann; Mark Bartholomä; Khalid Shoumariyeh; Jonas S Jutzi; Julius Wehrle; Christine Dierks; Heiko Becker; Annette Schmitt-Graeff; Marie Follo; Dietmar Pfeifer; Jan Rohr; Sebastian Fuchs; Stephan Ehl; Frederike A Hartl; Susana Minguet; Cornelius Miething; Florian H Heidel; Nicolaus Kröger; Ioanna Triviai; Tilman Brummer; Jürgen Finke; Anna L Illert; Eliana Ruggiero; Chiara Bonini; Justus Duyster; Heike L Pahl; Steven W Lane; Geoffrey R Hill; Bruce R Blazar; Nikolas von Bubnoff; Erika L Pearce; Robert Zeiser
Journal:  Sci Transl Med       Date:  2018-02-21       Impact factor: 17.956

Review 7.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

8.  Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Authors:  Morten Orebo Holmström; Caroline Hasselbalch Riley; Vibe Skov; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

9.  Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.

Authors:  Mia Aaboe Jørgensen; Morten Orebo Holmström; Evelina Martinenaite; Caroline Hasselbalch Riley; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

Review 10.  Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.

Authors:  Vincenzo Nasillo; Giovanni Riva; Ambra Paolini; Fabio Forghieri; Luca Roncati; Beatrice Lusenti; Monica Maccaferri; Andrea Messerotti; Valeria Pioli; Andrea Gilioli; Francesca Bettelli; Davide Giusti; Patrizia Barozzi; Ivana Lagreca; Rossana Maffei; Roberto Marasca; Leonardo Potenza; Patrizia Comoli; Rossella Manfredini; Antonino Maiorana; Enrico Tagliafico; Mario Luppi; Tommaso Trenti
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.